1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Semaglutide |
| brand | String | Ozempic (T2DM SC), Wegovy (obesity SC), Rybelsus (oral T2DM) |
| structure | File | |
| classes | List of String, delimiter: , | [[GLP-1 receptor agonist]] · [[Antidiabetic medicines|Antidiabetic]] · [[Anti-obesity medicines|Anti-obesity]] · [[Cardiovascular risk reduction]] agent |
| mechanism | String | Long-acting agonist of the [[GLP-1 receptor]]. |
| uses | String | [[Type 2 diabetes mellitus]] · [[Obesity]] · [[Cardiovascular risk reduction]] in obesity without diabetes · [[MASH]] with stage 2–3 fibrosis · [[Chronic kidney disease]] in T2DM |
| starting_dose | String | Ozempic: 0.25 mg SC weekly × 4 wk'"`UNIQ--ref-00000245-QINU`"' · Wegovy: 0.25 mg SC weekly × 4 wk'"`UNIQ--ref-00000246-QINU`"' · Rybelsus: 3 mg PO daily × 30 d'"`UNIQ--ref-00000247-QINU`"' |
| preparations | String | Pre-filled multi-dose pen (0.25 / 0.5 / 1 / 2 mg, Ozempic;'"`UNIQ--ref-00000248-QINU`"' 0.25 / 0.5 / 1 / 1.7 / 2.4 mg, Wegovy'"`UNIQ--ref-00000249-QINU`"') · Oral tablet 3 / 7 / 14 mg co-formulated with SNAC absorption enhancer (Rybelsus)'"`UNIQ--ref-0000024A-QINU`"' |
| fda_max | String | 2 mg/wk SC (Ozempic)'"`UNIQ--ref-0000024B-QINU`"' · 2.4 mg/wk SC (Wegovy)'"`UNIQ--ref-0000024C-QINU`"' · 14 mg PO daily (Rybelsus)'"`UNIQ--ref-0000024D-QINU`"' |
| pill_id | Text | |
| routes | List of String, delimiter: , | Subcutaneous (abdomen • thigh • upper arm)'"`UNIQ--ref-0000024E-QINU`"' · Oral (Rybelsus only • on empty stomach with ≤120 mL water • ≥30 min before any food/drink/other oral medicine)'"`UNIQ--ref-0000024F-QINU`"' |
| onset | String | Glycemic effect within days;<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> full weight effect over months'"`UNIQ--ref-00000250-QINU`"' |
| duration | String | ~7 days (weekly SC dosing)'"`UNIQ--ref-00000251-QINU`"' · ~24 h (oral)'"`UNIQ--ref-00000252-QINU`"' |
| halflife | String | ~165 hours (~1 week), among the longest of any GLP-1 RA'"`UNIQ--ref-00000253-QINU`"' |
| bioavailability | String | SC ~89%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> · Oral ~0.4–1% (SNAC-enhanced)'"`UNIQ--ref-00000254-QINU`"' |
| pregnancy | String | |
| legal | String | Rx-only;'"`UNIQ--ref-00000256-QINU`"' not a controlled substance |
